GREENFIELD, Ind., Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is underway.
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
Elanco Launches Varenzin™-CA1 (molidustat oral suspension) – the First-of-its-Kind Oral Treatment for Anemia in Cats with Chronic Kidney Disease
Elanco Releases 2022 Environmental, Social and Governance Report, Demonstrating Sustainability Progress in Internal Operations and Customer Collaborations
The FDA has conditionally approved molidustat oral suspension (Varenzin-CA1; Elanco Animal Health) for the management of nonregenerative anemia in cats with chronic kidney disease (CKD). Molidustat oral suspension is the first FDA approval for a drug that helps to control nonregenerative anemia in cats.
Elanco Announces FDA Approval of Bexacat™ (bexagliflozin tablets) – the First-of-its-Kind Oral Feline Diabetes Treatment Option
Elanco Animal Health Incorporated (ELAN: NYSE) and Royal DSM have created a strategic alliance connecting two leading, sustainability-focused companies to address one of society’s most significant opportunities of the decade, mitigating climate change by reducing greenhouse gas emissions from farming. Elanco has secured the exclusive U.S. licensing rights to develop, manufacture and commercialize Bovaer® for beef and dairy cattle.
GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) (“Elanco”) today announced the commencement of a cash tender offer (the “Offer”) for up to $250 million aggregate principal amount of its 4.272% Senior Notes due 2023 (CUSIP No. 28414HAE3) (the “Notes”), upon the terms and conditions set forth in the Offer to Purchase dated March 29, 2022.
Animal health giant Elanco completed the sale of a pair of manufacturing facilities to TriRx Pharmaceutical Services, a Connecticut-based CDMO.
Elanco Closes Acquisition of Kindred Biosciences